Longevity - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Autoimmune thyroiditis Part 3 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 3 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness. This last segment will bring it all together and give practical ways to use this information. 

Autoimmune thyroiditis Part 2 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

This is Part 2 of Dr. Holtorf’s 3-part series on autoimmune thyroiditis as a core cause of hypothalamic pituitary dysfunction, mitochondrial dysfunction, obesity and systemic illness

Autoimmune thyroiditis Part 1 - Kent Holtorf, MD (2021 Conference) (LDN, low dose naltrexone)

Strategies for reducing excess body fat... - Jill Brook, MA (2021 Conference) (LDN, low dose naltrexone)

Galyn Forster, MS, LPC - Treatment of Psychiatric Disorders (2016 Conference) (LDN, low dose naltrexone)

Download Mr. Forster's Psych Disorders Presentation

Microbiome Medicine: Clinical Correlations From The Trenches - Sarah Zielsdorf, MD, MS (2021 Conference) (LDN, low dose naltrexone)

In her presentation, Dr. Zielsdorf shares the importance and complexity of the human microbiome and best practices (from her own clinical experience) for restoring the gut microbiome and intestinal barrier.

Pamela Smith, MD - LDN Use in Cognitive Decline, Lyme Disease, and Hashimoto’s Thyroiditis (2019 Conference) (LDN, low dose naltrexone)

Leonard Weinstock, MD - Mast cell activation syndrome and potential role for LDN (2019 Conference) (LDN, low dose naltrexone)

Leonard Weinstock, MD discusses LDN  for MCAS and SIBO at the LDN 2019 Conference. He discusses the etiology, symptoms, testing, and therapy for MCAS, SIBO, and POTS; and presents related cases.